Development of a Native Fractionation Antigen Microarray for Autoantibody Profiling in Breast Cancer
Annual rept. 15 Sep 2009-14 Sep 2010
BRIGHAM AND WOMENS HOSPITAL BOSTON MA
Pagination or Media Count:
The humoral response of a cancer patient may allow earlier detection of cancer than current methods allow. If so, the serum autoantibody repertoire from cancer patients might be exploited for autoantibody profiling, and aid in the serological diagnosis of cancer. In this summary, we report the development of a whole proteome native antigen microarray for human breast cancer. This was accomplished by using a 2-D liquid chromatography fractionation strategy, where the 1st dimension is separation by isoelectric points and the 2nd dimension is separation by hydrophobicity. Using this platform and sera from stage 1 and 2 invasive ductal carcinoma of the breast as well as normal controls, we identified antigen containing fractions that were significantly differentially reactive with the cancer sera p0.05. Receiver operator characteristics curves were plotted for the top 5 reactive fractions and the area under the curve AUC was calculated. Our findings showed that when combined, the 5 reactive fractions have an AUC of 0.898 for stage 1 breast cancers versus normal controls, and an AUC of 0.82 for stage 2 breast cancers versus normal controls. Our preliminary results demonstrate that we have successfully developed a platform for autoantibody profiling, and that there are specific immune response signatures that might serve as potential biomarkers.
- Medicine and Medical Research